Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapys

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 1, 2014, Pages 110-123

  Pepinsky, R Blake ^a   Arndt, Joseph W ^a   Quan, Chao ^a   Gao, Yan ^a   Quintero Monzon, Omar ^a   Lee, Xinhua ^a   Mi, Sha ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN CONTAINING NOGO RECEPTOR INTERACTING PROTEIN 1; LINGO 1 LI81 FAB COMPLEX; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LI81; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RATS;

EID: 84903523368     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211771     Document Type: Article

References (48)

1. Ahmed Z, Douglas MR, John G, Berry M, and Logan A (2013) AMIGO3 is an NgR1/p75 co-receptor signalling axon growth inhibition in the acute phase of adult central nervous system injury. PLoS One 8:e61878.
2. Aires da Silva F, Corte-Real S, and Goncalves J (2008) Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 22:301-314.
3. Bella J, Hindle KL, McEwan PA, and Lovell SC (2008) The leucine-rich repeat structure. Cell Mol Life Sci 65:2307-2333.
4. Bourikas D, Mir A, and Walmsley AR (2010) LINGO-1-mediated inhibition of oligodendrocyte differentiation does not require the leucine-rich repeats and is reversed by p75(NTR) antagonists. Mol Cell Neurosci 45:363-369.
5. Cen J, Wu H, Wang J, Ren X, Zhang H, Wang J, Wan Y, and Deng Y (2013) Local injection of lentivirus encoding LINGO-1-shRNA promotes functional recovery in rats with complete spinal cord transection. Spine 38:1632-1639.
6. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, and Paul SM, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloidbeta metabolism and half-life. J Neurosci 23:8844-8853. (Pubitemid 37210896)
7. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
8. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. (Pubitemid 41742764)
9. Fu QL, Hu B, Wu W, Pepinsky RB, Mi S, and So KF (2008) Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalmol Vis Sci 49:975-985.
10. Garg A and Balthasar JP (2009) Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J 11:553-557.
11. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, and Pieters H, et al. (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementaritydetermining-region diversity. Nat Biotechnol 23:344-348. (Pubitemid 41094423)
12. Jepson S, Vought B, Gross CH, Gan L, Austen D, Frantz JD, Zwahlen J, Lowe D, Markland W, and Krauss R (2012) LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular selfinteractions. J Biol Chem 287:22184-22195.
13. Ji B, Li M, Wu WT, Yick LW, Lee X, Shao Z, Wang J, So KF, McCoy JM, and Pepinsky RB, et al. (2006) LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci 33:311-320. (Pubitemid 44692494)
14. Kajander T, Kuja-Panula J, Rauvala H, and Goldman A (2011) Crystal structure and role of glycans and dimerization in folding of neuronal leucine-rich repeat protein AMIGO-1. J Mol Biol 413:1001-1015.
15. Karaulanov EE, Böttcher RT, and Niehrs C (2006) A role for fibronectin-leucine-rich transmembrane cell-surface proteins in homotypic cell adhesion. EMBO Rep 7:283-290.
16. Kontermann RE (2009) Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23:93-109.
17. Krissinel E and Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372:774-797. (Pubitemid 47321791)
18. Lawrence MC and Colman PM (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234:946-950. (Pubitemid 24027225)
19. Lee X, Yang Z, Shao Z, Rosenberg SS, Levesque M, Pepinsky RB, Qiu M, Miller RH, Chan JR, and Mi S (2007) NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci 27:220-225. (Pubitemid 46089975)
20. Lee X, Shao Z, Sheng G, Pepinsky B, and Mi S (2014) LINGO-1 regulates oligodendrocyte differentiation by inhibiting ErbB2 translocation and activation in lipid rafts. Mol Cell Neurosci 60C:36-42.
21. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, and Rosenberry TL, et al. (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 20:2576-2578.
22. McCoy AJ (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr 63:32-41.
23. McDonald CL, Bandtlow C, and Reindl M (2011) Targeting the Nogo receptor complex in diseases of the central nervous system. Curr Med Chem 18:234-244.
24. McEwan PA, Scott PG, Bishop PN, and Bella J (2006) Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol 155:294-305. (Pubitemid 44278663)
25. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, Wong WM, Wang L, Su H, and Chu TH, et al. (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13:1228-1233. (Pubitemid 47530642)
26. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, and Sands B, et al. (2004) LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 7:221-228. (Pubitemid 38280445)
27. Mi S, McCoy J, Pepinsky RB, and Lee DHS (2010) inventors; Biogen Idec, Inc., assignee. Nogo receptor binding protein. U.S. patent 7,785,829. 2010 Aug 31.
28. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, Chang J, Thill G, Levesque M, and Zhang M, et al. (2005) LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 8:745-751. (Pubitemid 43085840)
29. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, Zhang Y, Shields CB, Zhang Y, and Miklasz S, et al. (2009) Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 65:304-315.
30. Mi S, Pepinsky RB, and Cadavid D (2013) Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 27:493-503.
31. Mosyak L, Wood A, Dwyer B, Buddha M, Johnson M, Aulabaugh A, Zhong X, Presman E, Benard S, and Kelleher K, et al. (2006) The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J Biol Chem 281:36378-36390. (Pubitemid 46041372)
32. Nose A, Mahajan VB, and Goodman CS (1992) Connectin: a homophilic cell adhesion molecule expressed on a subset of muscles and the motoneurons that innervate them in Drosophila. Cell 70:553-567.
33. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. (Pubitemid 27085611)
34. Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL, Garcia KC, and He Z (2005) A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 45:345-351. (Pubitemid 40188202)
35. Pepinsky RB, Shao Z, Ji B, Wang Q, Meng G, Walus L, Lee X, Hu Y, Graff C, and Garber E, et al. (2011) Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther 339:519-529.
36. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, and Graff C, et al. (2010) Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 19:954-966.
37. Saha N, Kolev MV, Semavina M, Himanen J, and Nikolov DB (2011) Ganglioside mediate the interaction between Nogo receptor 1 and LINGO-1. Biochem Biophys Res Commun 413:92-97.
38. Seabold GK, Wang PY, Chang K, Wang CY, Wang YX, Petralia RS, and Wenthold RJ (2008) The SALM family of adhesion-like molecules forms heteromeric and homomeric complexes. J Biol Chem 283:8395-8405.
39. Shaikh TR, Gao H, Baxter WT, Asturias FJ, Boisset N, Leith A, and Frank J (2008) SPIDER image processing for single-particle reconstruction of biological macromolecules from electron micrographs. Nat Protoc 3:1941-1974.
40. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, and McCoy JM, et al. (2005) TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45:353-359. (Pubitemid 40188203)
41. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857. (Pubitemid 39307054)
42. Stein T and Walmsley AR (2012) The leucine-rich repeats of LINGO-1 are not required for self-interaction or interaction with the amyloid precursor protein. Neurosci Lett 509:9-12.
43. Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, Long F, and Murshudov GN (2004) REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr 60:2184-2195. (Pubitemid 41742770)
44. Wen D, Corina K, Chow EP, Miller S, Janmey PA, and Pepinsky RB (1996) The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35:9700-9709. (Pubitemid 26302982)
45. Winn MD, Isupov MN, and Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr Sect D-Biol Crystallogr 57:122-133. (Pubitemid 32062682)
46. Winzor DJ and Scheraga HA (1963) Studies of chemically reacting systems on Sephadex I. Chromatographic demonstration of the Gilbert theory. Biochemistry 2:1263-1267.
47. Yu C, Crispin M, Sonnen AF, Harvey DJ, Chang VT, Evans EJ, Scanlan CN, Stuart DI, Gilbert RJ, and Davis SJ (2011) Use of the a-mannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells. Acta Crystallogr Sect F Struct Biol Cryst Commun 67:785-789.
48. Zoltowski BD and Crane BR (2008) Light activation of the LOV protein vivid generates a rapidly exchanging dimer. Biochemistry 47:7012-7019. (Pubitemid 351956350)